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EDITORIAL
Plasma processes and polymers third special issue on plasma
and cancer
This issue of Plasma Processes and Polymers is the third in a
series on the applications of low temperature plasma (LTP)
against cancer, or “plasma oncology.” The papers in this issue
are inspired from the talks given at the third International
Workshop on Plasma for Cancer Treatment (IWPCT) which
took place on April 11–12, 2016 in Washington, DC, USA.
IWPCT is an international workshop that was created in 2014
as a venue to share cutting edge plasma oncology research.
The first IWPCT was held in Washington DC, under the
co-chairmanship of Prof. Mounir Laroussi (Old Dominion
University) and Prof. Michael Keidar (George Washington
University). The second workshop, IWPCT-2, was held in
March 2015 in Nagoya, Japan under the chairmanship of
Prof.MasaruHori (NagoyaUniversity). Asmentioned above,
IWPCT-3 was held again in Washington DC in 2016 under
the co-chairmanship of Dr. Jerome Canady (Jerome Canady
Research Institute) and Dr. Jonathan Sherman (George
Washington University).
The application of LTP in the field of oncology is a topic
of growing importance within the discipline of Plasma
Medicine. Plasma Medicine is an interdisciplinary field of
research that emerged in the mid-1990s when seminal
investigations showed that LTP can effectively inactivate
various bacteria genera.[1–4] This early research quickly
expanded to determining the effects of LTP on eukaryotic
cells, first for wound healing[5–8] and later for cancer
treatment applications.[9–17] Figure 1 shows a brief summary
of the timeline and progress of the field of plasma medicine
for the past two decades. This timeline relates the major
milestones for low temperature atmospheric pressure plasma
applications in biology and medicine and does not include
thermal and low pressure plasma works.
Starting around the mid-2000s several investigators
reported on successful studies which showed that low
temperature plasmas can destroy cancerous cells in
vitro.[9–14] By 2010, some in vivo work was reported
which showed that plasma can reduce the size of cancer
tumors in animal models.[15–17] The mechanisms of action
of LTP on cancer cells include the induction of apoptosis
via caspases or mitochondrial dysfunction, cell cycle arrest
at the S-phase, DNA damage/double-strand breaks,
and increase of the intracellular concentrations of ROS
above tolerable thresholds. Investigators reported
that reactive oxygen species, ROS, produced by the
plasma are implicated in the initiation of these effects on
cells/biomolecules in general and cancer cells in
particular.[7,8,13,14,18,19] The plasma-produced ROS have
been implicated in penetrating the cells and inducing
secondary reactions within the cells and/or triggering cell
signaling cascades involved in processes such as apoptosis
that ultimately lead to the death of cancer cells. More
importantly, under optimal conditions, it appears that LTP
preferentially kills cancerous cells while leaving healthy
ones mostly undamaged. This selectivity is very crucial if
LTP is to be considered as a viable technology for a new
cancer therapy.
Eighteen invited talks were delivered at IWPCT-3 along
with fourteen poster presentations. Researchers hailing from
ten countries attended the workshop, which allowed for
ample discussions and excellent collaboration opportunities.
This special issue contains nine papers which cover
fundamental studies on the effects of LTP on cancer cells
as well as applied investigations that aim to evaluate the
possibility of using LTP as a basis for a novel and effective
cancer therapy. Several of these papers discuss the correlation
between plasma chemistry (especially RONS production),
the plasma induced chemistry in the aqueous phase, and the
observed cellular effects, including the importance of specific
reactive species such as singlet oxygen and hydrogen
peroxide. There is also general consensus that many factors
dictate the biological outcome after plasma exposure.
Examples of some of these factors include plasma operating
parameters such as feed gas, flow rate, and power as well as
biological factors such as cell line and concentration, medium
chemical composition, and direct versus indirect exposure. In
addition, plasma activated media (PAM) as an alternative to
the direct plasma treatment approach is discussed in a couple
of the papers. Evaluation of the efficacy of PAM against some
cancer lines is presented, including the impact of storage and
temperature.
The guest editors would like to thank Managing Editor,
Dr. Renate Foerch, for coordinating this special issue with
great care. The guest editors would also like to thank
the authors for their valuable contributions to this issue.
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acknowledged.
The guest editors
Mounir Laroussi1
Annemie Bogaerts2
Nazir Barekzi1
1Old Dominion University
2University of Antwerp
REFERENCES
[1] M. Laroussi, IEEE Trans. Plasma Sci. 1996, 24, 1188.
[2] K. Kelly-Wintenberg, T. C. Montie, C. Brickman, J. R. Roth, A. K.
Carr, K. Sorge, L. C. Wadworth, P. P. Y Tsai, J. Ind. Microbiol.
Biotechnol. 1998, 20, 69.
[3] H. W. Herrmann, I. Henins, J. Park, G. S. Selwyn, Phys. Plasmas
1999, 6, 2284.
[4] M. Laroussi, IEEE Trans. Plasma Sci. 2002, 30, 1409.
[5] A. B. Shekhter, R. K. Kabisov, A. V. Pekshev, N. P. Kozlov, Yu. L.
Perov, Bull. Exp. Biol. Med. 1998, 126, 829.
[6] G. Isbary, G. Morfill, H. U. Schmidt, M. Georgi, K. Ramrath, J.
Heinlin, S. Karrer, M. Landthaller, T. Shimizu, B. Steffes, W.
Bunk, R. Monetti, J. L. Zimmermann, R. Pompl, W. Stolz, Br. J.
Dermatol. 2010, 163, 78.
[7] M. Laroussi, IEEE Trans. Plasma Sci. 2009, 37, 714.
[8] Th. von Woedtke, S. Reuter, K. Masur, K.-D. Weltmann, Phys.
Repts. 2013, 530, 291.
[9] S. Yonson, S. Coulombe, V. Leveille, R. Leask, J. Phys. D: Appl.
Phys. 2006, 39, 3508.
[10] G. Fridman,A.Brooks,M.Galasubramanian,A. Fridman,A.Gutsol,
V. Vasilets, H. Ayan, G. Friedman,Plasma Process. Polym. 2007, 4,
370.
[11] N. Barekzi, M. Laroussi, J. Phys. D: Appl. Phys. 2012, 45, 422002.
[12] J. Schlegel, J. Koritzer, V. Boxhammer, Clin. Plasma Med. 2013,
1, 2.
[13] M. Keidar, A. Shashurin, O. Volotskova, M. A. Stepp, P.
Srinivasan, A. Sandler, B. Trink, Phys. Plasmas 2013, 20,
057101.
[14] N. Barekzi, M. Laroussi, Plasma Process. Polym. 2013, 10,
1039.
[15] M. Vandamme, E. Robert, S. Pesnele, E. Barbosa, S. Dozias, J.
Sobilo, S. Lerondel, A. Le Pape, J-M. Pouvesle, Plasma Process.
Polym. 2010, 7, 264.
[16] J. Y. Kim, J. Ballato, P. Foy, T. Hawkins, Y. Wei, J. Li, et al.
Biosens. Bioelectron 2011, 28, 333.
[17] M. Keidar, R. Walk, A. Shashurin, P. Srinivasan, A. Sandler, S.
Dasgupta, R. Ravi, R. Guerrero-Preston, B. Trink, Br. J. Cancer.
2011, 105, 1295.
[18] D. Graves, J. Phys. D: Appl. Phys. 2012, 45, 263001.
[19] A. Bogaerts, M. Yusupov, J. van der Paal, C. C. W. Verlackt, E. C.
Neyts, Plasma Process. Polym. 2014, 11, 1156.
How to cite this article: Laroussi M, Bogaerts A,
Barekzi N. 2016. Plasma processes and polymers
third special issue on plasma and cancer. Plasma
Process Polym 13:1142–1143.
FIGURE 1 Timeline showing the progression of the LTP applications in biology and medicine for the past 20 years. By the time this special issue is
published, cancer related plasma research would have been ongoing for about one decade. The first conference entirely dedicated to plasma medicine was
the International Conference on Plasma Medicine (ICPM) that was established in 2007. In 2014, a workshop entirely dedicated to LTP cancer applications
was founded. This International Workshop on Plasma for cancer Treatment (IWPCT) meets annually. Many of the papers published in this special issue
are inspired from talks given at the IWPCT-3 (2016)
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